|
Post by nylefty on Sept 3, 2016 0:43:14 GMT -5
Looks like you are doing a little bit of soft bash saying that refil rate it's too small. (smip) Only trying to speak to the reality of the situation. Just spent some time to look at script counts over the past year. It is ugly. Very ugly. There are no more excuses. If Afrezza was a wonder drug, the diabetics would be demanding it. Word would be travelling like wildfire through social media. Doctors would be demanding it or at least wanting to know more to prescribe it. And, those using it would not quickly abandon the product. Something is horribly wrong and it is more than insurance and label issues.
Those that have been long tis stock for some time have been brainwashed by management and other long shareholders. (snip) I thought whiners and bashers with nothing constructive to say weren't welcome here. We seem to be under siege by newbie attackers.
|
|
|
Post by kball on Sept 3, 2016 5:57:02 GMT -5
Only trying to speak to the reality of the situation. Just spent some time to look at script counts over the past year. It is ugly. Very ugly. There are no more excuses. If Afrezza was a wonder drug, the diabetics would be demanding it. Word would be travelling like wildfire through social media. Doctors would be demanding it or at least wanting to know more to prescribe it. And, those using it would not quickly abandon the product. Something is horribly wrong and it is more than insurance and label issues.
Those that have been long tis stock for some time have been brainwashed by management and other long shareholders. (snip) I thought whiners and bashers with nothing constructive to say weren't welcome here. We seem to be under siege by newbie attackers. Agree on the negative newbies comment. OTOH interventions have been known to be helpful in many cases. Coming too late for others (like me) Perhaps coming in time for the many who no longer post (perhaps they were able to salvage some wealth).
|
|
|
Post by bioexec25 on Sept 3, 2016 7:17:57 GMT -5
Kball, too late for me as well.
The odds of the newbie being correct on most points are high and getting higher by the week but they are by no means a foregone conclusion. At the risk of falling into the just 2 more months trap, again, it is a little too soon to write Afrezza's obituary.
I see a lot of positive infrastructure being laid but admittedly it does feel like the docs just aren't prescribing. I sure do wish we could magically reach all PWD and let them co-decide the fate of Afrezza. Dream on.
|
|
|
Post by kingedxxxxx on Sept 3, 2016 9:42:11 GMT -5
I may appear as a new poster, but have followed MannKind since the day of the Adcom vote. I do not even like to invest or trade biotech stocks due to the uncertainty and likelihood that there will be capital raise after capital raise (due to a lack of revenues) coupled with most never making it. Even ones like Affymax that brought what looked like a very promising drug to the market, fell on its face when there were deaths related to its use. AFFY is now dissolving. On the other hand, I do have some shares of ADXS that has several possible drugs in the pipeline that look incredibly promising.
I occasionally posted on the MNKD Yahoo board, but mostly just kept trying to gather info from both sides. Then, I joined the "wrong" private MannKind board, but it did provide some more helpful info about the history of the company and data on the current state of the company. Anyway, when I did post, I always mentioned that the script numbers were the key and the single most important factor that would lead to MannKind's success or failure.
It is unbelievable that the scripts are so low. I don't care if MannKind did not even do ANY marketing. Based on the word already out there with all of the hype from social media, the diabetic community, and MannKind long shareholders, scripts should have moved up all on their own. It has become obvious after this amount of time that: 1. Diabetics are NOT demanding Afrezza. 2. Doctors are NOT demanding Afrezza for their patients. 3. Those that have tried Afrezza have discontinued its use. 4. Afrezza is obviously not performing at the level expected with those using it. 5. There have been many barriers that MannKind has failed to overcome to improve Afrezza's ability to reach the market - insurance, label, etc. 6. Sanofi did make an attempt to market Afrezza and ran from it after encountering most of the issues above.
MannKind has been on a path for failure for some time. Everyone that has been following this company for some time should have jumped ship by now or should have been on the short side. Management has been avoiding the truth and have screwed all shareholders, especially the ones that have been continuing to give the company life.
Honestly, I did not expect this. The way that those talked up Afrezza on the MannKind board and the way that those that have supposedly been using Afrezza have been talking it up, it surely looked like a much better product versus the competition. You cannot believe everything you read on a message board. LOL
Anyway, I decided I would stay on the sideline and keep a close eye on script counts and use that as the one clear decision of whether to buy back into this stock REGARDLESS OF STOCK PRICE and how cheap the stock appears. I have invested quite a bit of time researching and analyzing this company, which is why I am still around. Have kept looking for an opportunity to reload shares. Did not ever consider getting on the short side. However, at this point, it is highly doubtful that there will be a dramatic increase in scripts to prevent MannKind entering reorganization. Going to be no fun reading AF's comments stating that he told us all so.
|
|
|
Post by slugworth008 on Sept 3, 2016 9:50:19 GMT -5
I may appear as a new poster, but have followed MannKind since the day of the Adcom vote. I do not even like to invest or trade biotech stocks due to the uncertainty and likelihood that there will be capital raise after capital raise (due to a lack of revenues) coupled with most never making it. Even ones like Affymax that brought what looked like a very promising drug to the market, fell on its face when there were deaths related to its use. AFFY is now dissolving. On the other hand, I do have some shares of ADXS that has several possible drugs in the pipeline that look incredibly promising.
I occasionally posted on the MNKD Yahoo board, but mostly just kept trying to gather info from both sides. Then, I joined the "wrong" private MannKind board, but it did provide some more helpful info about the history of the company and data on the current state of the company. Anyway, when I did post, I always mentioned that the script numbers were the key and the single most important factor that would lead to MannKind's success or failure.
It is unbelievable that the scripts are so low. I don't care if MannKind did not even do ANY marketing. Based on the word already out there with all of the hype from social media, the diabetic community, and MannKind long shareholders, scripts should have moved up all on their own. It has become obvious after this amount of time that: 1. Diabetics are NOT demanding Afrezza. 2. Doctors are NOT demanding Afrezza for their patients. 3. Those that have tried Afrezza have discontinued its use. 4. Afrezza is obviously not performing at the level expected with those using it. 5. There have been many barriers that MannKind has failed to overcome to improve Afrezza's ability to reach the market - insurance, label, etc. 6. Sanofi did make an attempt to market Afrezza and ran from it after encountering most of the issues above.
MannKind has been on a path for failure for some time. Everyone that has been following this company for some time should have jumped ship by now or should have been on the short side. Management has been avoiding the truth and have screwed all shareholders, especially the ones that have been continuing to give the company life.
Honestly, I did not expect this. The way that those talked up Afrezza on the MannKind board and the way that those that have supposedly been using Afrezza have been talking it up, it surely looked like a much better product versus the competition. You cannot believe everything you read on a message board. LOL
Anyway, I decided I would stay on the sideline and keep a close eye on script counts and use that as the one clear decision of whether to buy back into this stock REGARDLESS OF STOCK PRICE and how cheap the stock appears. I have invested quite a bit of time researching and analyzing this company, which is why I am still around. Have kept looking for an opportunity to reload shares. Did not ever consider getting on the short side. However, at this point, it is highly doubtful that there will be a dramatic increase in scripts to prevent MannKind entering reorganization. Going to be no fun reading AF's comments stating that he told us all so.
What you talking 'bout Wilfred. And why wouldn't you pick up some cheap shares with your petty cash - just in case. I have a friend who uses Afrezza and loves it for reasons that have been expressed in countless threads and on social media. I'll buy and hold while you watch from the sidelines.
|
|
|
Post by centralcoastinvestor on Sept 3, 2016 10:02:51 GMT -5
I may appear as a new poster, but have followed MannKind since the day of the Adcom vote. I do not even like to invest or trade biotech stocks due to the uncertainty and likelihood that there will be capital raise after capital raise (due to a lack of revenues) coupled with most never making it. Even ones like Affymax that brought what looked like a very promising drug to the market, fell on its face when there were deaths related to its use. AFFY is now dissolving. On the other hand, I do have some shares of ADXS that has several possible drugs in the pipeline that look incredibly promising.
I occasionally posted on the MNKD Yahoo board, but mostly just kept trying to gather info from both sides. Then, I joined the "wrong" private MannKind board, but it did provide some more helpful info about the history of the company and data on the current state of the company. Anyway, when I did post, I always mentioned that the script numbers were the key and the single most important factor that would lead to MannKind's success or failure.
It is unbelievable that the scripts are so low. I don't care if MannKind did not even do ANY marketing. Based on the word already out there with all of the hype from social media, the diabetic community, and MannKind long shareholders, scripts should have moved up all on their own. It has become obvious after this amount of time that: 1. Diabetics are NOT demanding Afrezza. 2. Doctors are NOT demanding Afrezza for their patients. 3. Those that have tried Afrezza have discontinued its use. 4. Afrezza is obviously not performing at the level expected with those using it. 5. There have been many barriers that MannKind has failed to overcome to improve Afrezza's ability to reach the market - insurance, label, etc. 6. Sanofi did make an attempt to market Afrezza and ran from it after encountering most of the issues above.
MannKind has been on a path for failure for some time. Everyone that has been following this company for some time should have jumped ship by now or should have been on the short side. Management has been avoiding the truth and have screwed all shareholders, especially the ones that have been continuing to give the company life.
Honestly, I did not expect this. The way that those talked up Afrezza on the MannKind board and the way that those that have supposedly been using Afrezza have been talking it up, it surely looked like a much better product versus the competition. You cannot believe everything you read on a message board. LOL
Anyway, I decided I would stay on the sideline and keep a close eye on script counts and use that as the one clear decision of whether to buy back into this stock REGARDLESS OF STOCK PRICE and how cheap the stock appears. I have invested quite a bit of time researching and analyzing this company, which is why I am still around. Have kept looking for an opportunity to reload shares. Did not ever consider getting on the short side. However, at this point, it is highly doubtful that there will be a dramatic increase in scripts to prevent MannKind entering reorganization. Going to be no fun reading AF's comments stating that he told us all so.
Clearly you have given up on this company and its product. I disagree with you on so many issues raised above. My response to your post above can be read in the Castagna Manifesto thread, an extremely well thought out response to LFD written by Mike Castagna. Breaking into a heavily competitive space like diabetes isn't easy. In fact, it's much harder than I expected. With a give up attitude like yours, no one would have invented flight or the telegraph or any other important discovery. Afrezza is so ahead of its time, it will take time for doctors and patients to understand it's great benefits. With your obvious distaste for this company and its main product, why post here at all. Is it that you are trying to help us poor delusional longs see the light? Or do you have another agenda? Could this company fail, yes it's possible. But the condescending way you mock those that still believe that Afrezza can change the diabetes world is just insulting. The funny thing is, you write as though you know how this all ends. You don't and neither do I.
|
|
|
Post by op2778 on Sept 3, 2016 11:55:13 GMT -5
Again, i respect all opinions, included yours, but you are really a soft basher. When you said: The supposedly results from users....Are you kidding right? Do you read The CGM results? Do you think those users can manipulate those numbers on CGM? Well, man, i do really feel sorry for you....
the other sentence: i don't short.....If you are so sure about Afrezza failure and or MNKD failure, why are you waiting for a drop in price to Buy shares? Please, short all you can to The way to 0000000. Is far better than buying low and taking a risk to do few pennies selling on a spike. lOL
listen, I'm a small investor in MNKD, bought low (Thanks GOD) and I'm not following MNKD since Adcom (just 1yr following now, buying and selling). I think TS is The holy grial, probably Afrezza will fail, but at least they tried. So, keep going with Your soft bash and short please.
OP
|
|
|
Post by anderson on Sept 4, 2016 8:52:03 GMT -5
I may appear as a new poster, but have followed MannKind since the day of the Adcom vote. I do not even like to invest or trade biotech stocks due to the uncertainty and likelihood that there will be capital raise after capital raise (due to a lack of revenues) coupled with most never making it. Even ones like Affymax that brought what looked like a very promising drug to the market, fell on its face when there were deaths related to its use. AFFY is now dissolving. On the other hand, I do have some shares of ADXS that has several possible drugs in the pipeline that look incredibly promising.
I occasionally posted on the MNKD Yahoo board, but mostly just kept trying to gather info from both sides. Then, I joined the "wrong" private MannKind board, but it did provide some more helpful info about the history of the company and data on the current state of the company. Anyway, when I did post, I always mentioned that the script numbers were the key and the single most important factor that would lead to MannKind's success or failure.
It is unbelievable that the scripts are so low. I don't care if MannKind did not even do ANY marketing. Based on the word already out there with all of the hype from social media, the diabetic community, and MannKind long shareholders, scripts should have moved up all on their own. It has become obvious after this amount of time that: 1. Diabetics are NOT demanding Afrezza. 2. Doctors are NOT demanding Afrezza for their patients. 3. Those that have tried Afrezza have discontinued its use. 4. Afrezza is obviously not performing at the level expected with those using it. 5. There have been many barriers that MannKind has failed to overcome to improve Afrezza's ability to reach the market - insurance, label, etc. 6. Sanofi did make an attempt to market Afrezza and ran from it after encountering most of the issues above.
MannKind has been on a path for failure for some time. Everyone that has been following this company for some time should have jumped ship by now or should have been on the short side. Management has been avoiding the truth and have screwed all shareholders, especially the ones that have been continuing to give the company life.
Honestly, I did not expect this. The way that those talked up Afrezza on the MannKind board and the way that those that have supposedly been using Afrezza have been talking it up, it surely looked like a much better product versus the competition. You cannot believe everything you read on a message board. LOL
Anyway, I decided I would stay on the sideline and keep a close eye on script counts and use that as the one clear decision of whether to buy back into this stock REGARDLESS OF STOCK PRICE and how cheap the stock appears. I have invested quite a bit of time researching and analyzing this company, which is why I am still around. Have kept looking for an opportunity to reload shares. Did not ever consider getting on the short side. However, at this point, it is highly doubtful that there will be a dramatic increase in scripts to prevent MannKind entering reorganization. Going to be no fun reading AF's comments stating that he told us all so.
So you have no shares, but are concerned for the rest of us......why are there so many good hearten people out there that care that I am throwing money away on MNKD and not wanting to sell?
|
|
|
Post by figglebird on Sept 4, 2016 9:08:00 GMT -5
BC fear is fear and divorcing one from ones convictions is usually easy and requires little effort.
Be prepared to lose everything or sell.
Third option is insanity.
|
|
|
Post by tayl5 on Sept 4, 2016 11:10:34 GMT -5
BC fear is fear and divorcing one from ones convictions is usually easy and requires little effort. Be prepared to lose everything or sell. Third option is insanity. Why mess around? Most of us here go right to insanity. Being insane doesn't mean you're wrong, though.
|
|
|
Post by gamblerjag on Nov 13, 2016 17:20:00 GMT -5
Mannmade - You got #1 done!!!
|
|